EUVIMEDEUVIMED entdecken
Systematische Übersicht

The Safety and Efficacy of Anti‐Vascular Endothelial Growth Factor Biosimilars in Retinopathy of Prematurity

Elektra Tsivitanidou iD, Abdullah Shakeel iD, Omar Warda

Acta Paediatrica · 2025

DOI: 10.1111/apa.70400 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Acta Paediatrica, 2025. Verfasst von Elektra Tsivitanidou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Retinopathy of Prematurity, Biosimilar Pharmaceuticals, Bevacizumab, Angiogenesis Inhibitors. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Biosimilar anti‐vascular endothelial growth factor agents are cheaper alternatives to current treatments, but their safety and efficacy are unknown. This review aims to evaluate the safety and efficacy of biosimilar anti‐vascular endothelial growth factors in the management of retinopathy of prematurity.

Methods

A systematic review of the current literature was undertaken to identify studies that reported safety and efficacy outcomes of intravitreal administration anti‐vascular endothelial growth factor biosimilars in preterm infants with retinopathy of prematurity. Data were synthesised to assess safety, success and retreatment rates using random forest plots.

Results

Five studies met the inclusion criteria (382 eyes); three studies used bevacizumab biosimilars (217 eyes) and two used ranibizumab biosimilars (118 eyes). The overall adverse event rate was 0.5%. The pooled treatment success rates were 65% (95% CI: 58%–71%) with bevacizumab biosimilars and 46% (95% CI: 2%–95%) with ranibizumab biosimilars. Five eyes (1%) in the whole cohort required surgery: four in the bevacizumab and one in the ranibizumab group.

Conclusions

Biosimilar anti‐vascular endothelial growth factor agents demonstrated safety and reasonable efficacy. Biosimilars are a cost‐effective alternative and may improve clinical outcomes in low‐income countries. Randomised controlled trials should compare biosimilars to their reference biologic. Trial Registration PROSPERO: CRD420251010789

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinopathy of PrematurityBiosimilar PharmaceuticalsBevacizumabAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AHumansInfant, NewbornInfant, PrematureIntravitreal Injections

Stichwörter der Autor:innen

biosimilar pharmaceuticalsretinopathy of prematurityvascular endothelial growth factor

Substanzen

Biosimilar PharmaceuticalsBevacizumabAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Princess Alexandra Hospital NHS Trust, Harlow, UK.
  • Great Ormond Street Hospital NHS Trust, London, UK.

ORCID-Profile: Elektra Tsivitanidou, Abdullah Shakeel

Zitieren

APA

Tsivitanidou, E., Shakeel, A., & Warda, O. (2025). The Safety and Efficacy of Anti‐Vascular Endothelial Growth Factor Biosimilars in Retinopathy of Prematurity. Acta Paediatrica. https://doi.org/10.1111/apa.70400

Vancouver

Tsivitanidou E, Shakeel A, Warda O. The Safety and Efficacy of Anti‐Vascular Endothelial Growth Factor Biosimilars in Retinopathy of Prematurity. Acta Paediatrica. 2025. doi:10.1111/apa.70400

BibTeX
@article{Tsivitanidou2025,
  author = {Tsivitanidou, Elektra and Shakeel, Abdullah and Warda, Omar},
  title = {The Safety and Efficacy of Anti‐Vascular Endothelial Growth Factor Biosimilars in Retinopathy of Prematurity},
  journal = {Acta Paediatrica},
  year = {2025},
  doi = {10.1111/apa.70400}
}
Kostenlos starten →